Search

Your search keyword '"Van Elssen, Catharina"' showing total 40 results
Start Over Author "Van Elssen, Catharina"
40 results on '"Van Elssen, Catharina"'

1. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

3. Low Levels of Serum and Intracellular Vitamin C in Hospitalized COVID-19 Patients

Author

Boerenkamp, Lara S., primary, Gijsbers, Birgit L. M. G., additional, Ververs, Erik-Jan, additional, Pijpers, Eva M. S., additional, Spaetgens, Bart, additional, de Coninck, Aniek, additional, Germeraad, Wilfred T. V., additional, Wodzig, Will K. W. H., additional, Wieten, Lotte, additional, van Gorkom, Gwendolyn N. Y., additional, and van Elssen, Catharina H. M. J., additional

Published
2023
Full Text
View/download PDF

4. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

Author

van Zeeburg, Hester, primary, Kaur Singh, Satwinder, additional, Wagner-Drouet, Eva, additional, Platzbecker, Uwe, additional, Holderried, Tobias, additional, VAN Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Tore Gjertsen, Bjorn, additional, van de Loosdrecht, Arjan, additional, and Rovers, Jeroen, additional

Published
2023
Full Text
View/download PDF

6. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Lehmann, Sören, additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

7. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

8. No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial

Author

van Gorkom, Gwendolyn N. Y., primary, Boerenkamp, Lara S., additional, Gijsbers, Birgit L. M. G., additional, van Ojik, Heidi H., additional, Wodzig, Will K. W. H., additional, Wieten, Lotte, additional, Van Elssen, Catharina H. M. J., additional, and Bos, Gerard M. J., additional

Published
2022
Full Text
View/download PDF

9. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M., primary, Al-Badri, Waleed K. W., additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, van Elssen, Catharina H. M. J., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, van Gorkom, Gwendolyn N. Y., additional, Gradowska, Patrycja, additional, Greuter, Marjolein J. E., additional, Griskevicius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, Janssen, Jeroen J. W. M., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

10. Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?

Author

Boerenkamp, Lara S., primary, Pothast, Cilia R., additional, Dijkland, Romy C., additional, van Dijk, Kayleigh, additional, van Gorkom, Gwendolyn N. Y., additional, van Loo, Inge H. M., additional, Wieten, Lotte, additional, Halkes, Constantijn J. M., additional, Heemskerk, Mirjam H. M., additional, and Van Elssen, Catharina H. M. J., additional

Published
2022
Full Text
View/download PDF

16. The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands.

Author

van Gorkom, Gwendolyn, Van Elssen, Catharina, Janssen, Ian, Groothuis, Siebren, Evers, Silvia, and Bos, Gerard

Subjects
*HEMATOPOIETIC stem cell transplantation
Abstract

Background: Allogeneic haematopoietic stem cell transplantation (HSCT) is increasingly used, but this treatment is complex and costly. As clinical outcomes of HSCT with matched unrelated donor (MUD) and haploidentical donors are similar, costs could influence donor choice. Method: We retrospectively compared resource utilisation and costs of HSCT using the three different donor types (matched related donor (MRD) (n = 32), haploidentical related (n = 30) and MUD (n = 60)) within the first year after transplantation. Costs were analysed through a bottom‐up method. Non‐parametric bootstrapping was applied to test for statistical differences in costs. Subgroup analyses were performed to identify predictors for costs. Results: Cost pre‐transplant for search and acquisition of the graft were significantly higher in MUD HSCT (€35 222) versus MRD and haploidentical HSCT (€15 356 and €16 097 respectively). The costs of haploidentical HSCT were the highest in the transplant phase. Main cost factors were inpatient days and medication. Overall, the costs for haploidentical and MUD HSCT were similar (€115 724 for MUD, €113 312 for haploidentical). Conclusion: Our study suggests no difference in total transplantation costs between allogeneic HSCT using a MUD or a haploidentical donor. Since clinical outcomes seem similar as well, the choice of donor type might be based on availability, speed and logistics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. T cells fail to develop in the human skin-cell explants system; an inconvenient truth

Author

Vanderlocht Joris, Lumeij Stijn BJ, Tonnaer Siebe, van der Stegen Sjoukje JC, Huijskens Mirelle JAJ, Van Elssen Catharina HMJ, Meek Bob, Kirkland Mark A, Hesselink Reinout, Germeraad Wilfred TV, and Bos Gerard MJ

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Haplo-identical hematopoietic stem cell (HSC) transplantation is very successful in eradicating haematological tumours, but the long post-transplant T-lymphopenic phase is responsible for high morbidity and mortality rates. Clark et al. have described a skin-explant system capable of producing host-tolerant donor-HSC derived T-cells. Because this T-cell production platform has the potential to replenish the T-cell levels following transplantation, we set out to validate the skin-explant system. Results Following the published procedures, while using the same commercial components, it was impossible to reproduce the skin-explant conditions required for HSC differentiation towards mature T-cells. The keratinocyte maturation procedure resulted in fragile cells with minimum expression of delta-like ligand (DLL). In most experiments the generated cells failed to adhere to carriers or were quickly outcompeted by fibroblasts. Consequently it was not possible to reproduce cell-culture conditions required for HSC differentiation into functional T-cells. Using cell-lines over-expressing DLL, we showed that the antibodies used by Clark et al. were unable to detect native DLL, but instead stained 7AAD+ cells. Therefore, it is unlikely that the observed T-lineage commitment from HSC is mediated by DLL expressed on keratinocytes. In addition, we did confirm expression of the Notch-ligand Jagged-1 by keratinocytes. Conclusions Currently, and unfortunately, it remains difficult to explain the development or growth of T-cells described by Clark et al., but for the fate of patients suffering from lymphopenia it is essential to both reproduce and understand how these co-cultures really "work". Fortunately, alternative procedures to speed-up T-cell reconstitution are being established and validated and may become available for patients in the near future.

Published
2011
Full Text
View/download PDF

23. Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Author

Van Zeeburg, Hester, Wagner Drouet, Eva, Platzbecker, Uwe, Holderried, Tobias A.W., Van Elssen, Catharina, Giagounidis, Aristoteles, Lehmann, Soren, Rovers, Jeroen, Gjertsen, Bjorn T., and van de Loosdrecht, Arjan A.

Abstract

Background.Active immunotherapy relies on the patient's immune system for induction of an effective immune response. Not only the frequency, number and exhaustion or activation status of CD8 T cells is important for an efficacious tumor cell lysis, but the quality, number and distribution of different antigen presenting cells is of equal importance. Vididencel is an allogeneic leukemia-derived dendritic cell vaccine used in AML patients in first complete remission (CR1/CRi), but with MRD positivity, to mount an immune response through intradermal vaccination (ADVANCE-II, Clintrials.gov: NCT03697707). Intradermal vaccination is known to induce a specific immune response, by recruitment of skin and blood derived dendritic cells, which process antigen and present them to the immune system (Zuo et al., 2021). In this study circulating dendritic cells and monocytes have been investigated before and during vaccination to investigate the effect of vididencel treatment on the composition of antigen presenting cells in relation to clinical responses.

Published
2023
Full Text
View/download PDF

24. Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Author

van de Loosdrecht, Arjan A., Wagner Drouet, Eva, Platzbecker, Uwe, Holderried, Tobias A.W., Van Elssen, Catharina, Giagounidis, Aristoteles, Lehmann, Soren, Van Zeeburg, Hester, Rovers, Jeroen, and Gjertsen, Bjorn T.

Abstract

Background.Maintaining remission in AML after intensive chemotherapy continues to be a challenge, specifically in patients with measurable residual disease (MRD+). Immunotherapy could be an effective way to induce durable disease control for patients in remission. This phase 2 study used an allogenic leukemia-derived dendritic cell vaccine to induce an effective anti-leukemic response to control or eradicated MRD, leading to durable disease control. (ADVANCE-II, Clintrials.gov: NCT03697707).

Published
2023
Full Text
View/download PDF

26. Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination

Author

Oth, Tammy, Vanderlocht, Joris, Van Elssen, Catharina H. M. J., Bos, Gerard M. J., and Germeraad, Wilfred T. V.

Subjects
Article Subject
Abstract

A coordinated cellular interplay is of crucial importance in both host defense against pathogens and malignantly transformed cells. The various interactions of Dendritic Cells (DC), Natural Killer (NK) cells, and T helper (Th) cells can be influenced by a variety of pathogen-associated molecular patterns (PAMPs) and will lead to enhanced CD8+ effector T cell responses. Specific Pattern Recognition Receptor (PRR) triggering during maturation enables DC to enhance Th1 as well as NK helper cell responses. This effect is correlated with the amount of IL-12p70 released by DC. Activated NK cells are able to amplify the proinflammatory cytokine profile of DC via the release of IFN-γ. The knowledge on how PAMP recognition can modulate the DC is of importance for the design and definition of appropriate therapeutic cancer vaccines. In this review we will discuss the potential role of specific PAMP-matured DC in optimizing therapeutic DC-based vaccines, as some of these DC are efficiently activating Th1, NK cells, and cytotoxic T cells. Moreover, to optimize these vaccines, also the inhibitory effects of tumor-derived suppressive factors, for example, on the NK-DC crosstalk, should be taken into account. Finally, the suppressive role of the tumor microenvironment in vaccination efficacy and some proposals to overcome this by using combination therapies will be described.

Published
2016
Full Text
View/download PDF

27. Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease

Author

Van Elssen, Catharina H.M.J., primary, Rashidian, Mohammad, additional, Vrbanac, Vladimir, additional, Wucherpfennig, Kai W., additional, Habre, Zeina el, additional, Sticht, Jana, additional, Freund, Christian, additional, Jacobsen, Johanne T., additional, Cragnolini, Juanjo, additional, Ingram, Jessica, additional, Plaisier, Loes, additional, Spierings, Eric, additional, Tager, Andrew M., additional, and Ploegh, Hidde L., additional

Published
2017
Full Text
View/download PDF

31. NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Author

Van Elssen, Catharina H. M. J. and Ciurea, Stefan O.

Abstract

After decades since the discovery of natural killer (NK) cells as potential effector cells fighting malignantly transformed and virally infected cells, little progress has been made in their clinical application. This yet unrealized therapeutic effect is presumably, at least in part, due to low numbers of functional NK cells that could be obtained from the peripheral blood relative to tumor burden. Our group hypothesized that a relatively small NK cell number to targeted malignant cells is the cause of a lack of clinical effect. We pursued obtaining large numbers of NK cells via ex vivo expansion using feeder cells that express membrane-bound IL-21. Early clinical studies demonstrate safety of administration of ex vivo expanded NK cells after transplantation using this method and suggest a therapeutic benefit in terms on decreasing relapse rate and possible control of viral infections post-transplant can be achieved. Successful application of NK cells after hematopoietic stem cell transplantation opens the possibility to effectively enhance the anti-tumor effect and decrease relapse rate post-transplant. Moreover, high doses of NK cells could prove more efficacious in enhancing anti-tumor effects, not only in hematological malignancies, with our without transplantation, but also in solid tumor oncology. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

34. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

Author

Brandão, Rita D, primary, Veeck, Jürgen, additional, Van de Vijver, Koen K, additional, Lindsey, Patrick, additional, de Vries, Bart, additional, van Elssen, Catharina HMJ, additional, Blok, Marinus J, additional, Keymeulen, Kristien, additional, Ayoubi, Torik, additional, Smeets, Hubert JM, additional, Tjan-Heijnen, Vivianne C, additional, and Hupperets, Pierre S, additional

Published
2013
Full Text
View/download PDF

38. Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells

Author

Van Elssen, Catharina H. M. J., primary, Vanderlocht, Joris, additional, Frings, Peter W. H., additional, Senden-Gijsbers, Birgit L. M. G., additional, Schnijderberg, Melanie C. A., additional, van Gelder, Michel, additional, Meek, Bob, additional, Libon, Christine, additional, Ferlazzo, Guido, additional, Germeraad, Wilfred T. V., additional, and Bos, Gerard M. J., additional

Published
2010
Full Text
View/download PDF

39. A randomised controlled phase II trial of preoperative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.

Author

Brandão, Rita D., Veeck, Jürgen, Van de Vijver, Koen K., Lindsey, Patrick, De Vries, Bart, Van Elssen, Catharina H. M. J., Blok, Marinus J., Keymeulen, Kristien, Ayoubi, Torik, Smeets, Hubert J. M., Tjan-Heijnen, Vivianne C., and Hupperets, Pierre S.

Subjects
CYCLOOXYGENASE 2, RANDOMIZED controlled trials, CELL lines, CANCER cells, BREAST cancer patients, ANTINEOPLASTIC agents, CELECOXIB
Abstract

Introduction: Cyclooxygenase-2 (COX-2) is frequently over-expressed in primary breast cancer. In transgenic breast cancer models, over-expression of COX-2 leads to tumour formation while COX-2 inhibition exerts anti-tumour effects in breast cancer cell lines. To further determine the effect of COX-2 inhibition in primary breast cancer, we aimed to identify transcriptional changes in breast cancer tissues of patients treated with the selective COX-2 inhibitor celecoxib. Methods: In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15). Gene expression in fresh-frozen pre-surgical biopsies (before treatment) and surgical excision specimens (after treatment) was profiled by using Affymetrix arrays. Differentially expressed genes and altered pathways were bioinformatically identified. Expression of selected genes was validated by quantitative PCR (qPCR). Immunohistochemical protein expression analyses of the proliferation marker Ki-67, the apoptosis marker cleaved caspase-3 and the neo-angiogenesis marker CD34 served to evaluate biological response. Results: We identified 972 and 586 significantly up- and down-regulated genes, respectively, in celecoxib-treated specimens. Significant expression changes in six out of eight genes could be validated by qPCR. Pathway analyses revealed over-representation of deregulated genes in the networks of proliferation, cell cycle, extracellular matrix biology, and inflammatory immune response. The Ki-67 mean change relative to baseline was -29.1% (P = 0.019) and -8.2% (P = 0.384) in the treatment and control arm, respectively. Between treatment groups, the change in Ki-67 was statistically significant (P = 0.029). Cleaved caspase-3 and CD34 expression were not significantly different between the celecoxib-treated and placebo-treated groups. Conclusions: Short-term COX-2 inhibition by celecoxib induces transcriptional programs supporting anti-tumour activity in primary breast cancer tissue. The impact on proliferation-associated genes is reflected by a reduction of Ki-67 positive cells. Therefore, COX-2 inhibition should be considered as a treatment strategy for further clinical testing in primary breast cancer. Trial registration: ClinicalTrials.gov NCT01695226 [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

40. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J, Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W, Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J F M, Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W J, Bargetzi, Mario, Klein, Saskia K, Gadisseur, Alain, Westerweel, Peter E, Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A, Hoogendoorn, Mels, Legdeur, Marie-Cecile J C, Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T, Janssen, Jeroen J W M, Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J M, van Elssen, Catharina H M J, Manz, Markus G, Floisand, Yngvar, and Ossenkoppele, Gert J

Subjects
hemic and lymphatic diseases, 610 Medizin und Gesundheit, 3. Good health
Abstract

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% ± 2% standard error and overall survival, 54% ± 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.

Catalog

Books, media, physical & digital resources
See catalog results